-
2023-507031-38-00
5
2023-01-09
Severe viral lung infections
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2023-506838-68-00
9
2020-12-10
Renal cell carcinoma
-
2025-523486-17-00
5
2026-06-16
Obesity
-
2025-521587-35-00
5
2026-06-03
Metastatic colorectal cancer
-
2025-523106-32-00
5
2026-05-25
Obesity or Overweight and Type 2 Diabetes
-
2025-524160-38-00
5
2026-05-12
Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorect
-
2025-523104-71-00
5
2026-05-08
Obesity or Overweight Without Type 2 Diabetes
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2024-514874-36-01
4
2026-04-17
Refractory angina due to obstructive coronary artery disease
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-521730-28-00
4
2026-03-30
Colorectal Cancer with Cancer Cachexia
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-521670-34-00
5
2026-03-04
Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or
-
2025-521873-15-00
9
2026-02-09
Metastatic hormone-sensitive prostate cancer
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2025-523391-22-01
6
2026-01-20
Atrial fibrillation
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-520164-33-00
5
2025-12-09
Non-Small Cell Lung Cancer
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel